New hope and advances in prostate cancer treatment

  • by
prostate cancer

Prostate cancer is the most common cancer in men

With over 207,000 newly diagnosed cases in the U.S. annually, prostate cancer is the second most widespread cancer in men in the U.S. 

While localized treatment modalities often cure patients with localized disease, approximately 30% demonstrate biochemical relapse at ten years.

The ideal management of these patients remains elusive at present. Radiation treatment given for suspected recurrent malignant disease after a period of observation after prostatectomy, also known as salvage radiation therapy (SRT), provides long-term benefits in some patients, and the use of androgen deprivation treatment (ADT) continues to be debatable.

While ADT effectively reduces serum PSA levels in the majority of patients, its long-term benefits on survival and quality of life remain unclear. Data emphasize the incidence of accumulative toxicities with ADT, which may offset any potential survival benefit from early intervention and impact the life quality.

Department of Oncology, Tel-Aviv Sourasky Medical Center, Affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel

Prostate cancer diagnosis

The natural history of men with biochemically relapsed, non-castrate prostate cancer is quite mixed. They may remain asymptomatic and free of clinical evidence of disease for many years

Prostate cancer treatment

PectaSol® Modified Citrus Pectin (P-MCP; ecoNugenics Inc, Santa Rosa, CA, USA) is derived from the pith of citrus fruit peels and treated with enzymes, pH, and temperature. It is an orally administered competitive inhibitor of galectin-3 (Gal-3), a carbohydrate-binding protein involved in cancer pathogenesis.

P-MCP is a dietary supplement form of pectin comprised of low-molecular-weight and low degree of esterification to allow absorption from the small intestinal epithelium into the circulation.

prostate cancer

Prostate cancer symptoms – Inclusion Criteria

Eligible patients were ≥21 years old and had histologically proven prostatic adenocarcinoma. All participants had undergone radical prostatectomy and/or external beam radiation therapy

Toxicity and Disease Status at Follow-Up Monthly Assessments

Patients were evaluated for toxicities, physical exams, serum PSA, testosterone, CRP, and galectin-3 levels.

Statistical Analysis

The analysis was performed using the first six months of administration with the investigational supplement.
  • This study’s primary efficacy endpoint was the rate of patients without PSA progression (defined as an increase of ≥25% from baseline) and/or patients with improvement (lengthening) of PSADT versus baseline.
  • PSADT calculation used the natural log of two divided by the slope found from measuring a linear regression with the natural log of PSA against time (months). All the available PSA measurements in the year before patient enrollment were used to calculate baseline pre-treatment PSADT.
  • The post-baseline PSADT was calculated using PSA levels obtained at baseline and monthly during treatment.
  • Secondary endpoints were the rate of patients without radiologic progression, toxicity, and treatment benefits according to the PSADT risk grouping (e.g., poor < 3 months, intermediate 3–8.99 months, and good ≥ nine months).
Please follow and like us:

Leave a Reply